戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ls (5 x 10(6) and 1 x 10(7) 19-28z CAR T per kilogram).
2 d 12 received a high dose (2.0x10(14) vg per kilogram).
3 0,000 US dollars) and high mass (more than 8 kilograms).
4 500 hertz and power density of 600 watts per kilogram.
5 sfusion with 20 ml per kilogram or 30 ml per kilogram.
6 ntigen receptor-modified T (CAR-T) cells per kilogram.
7  in patients who received a dose of 3 mg per kilogram.
8 the realization of the definition of the new kilogram.
9 nditions for the redefinition of the SI unit kilogram.
10 responding dose of either 25 IU or 65 IU per kilogram.
11 0 ml per kilogram as compared with 18 ml per kilogram.
12 red, giving a mass M = (9,982 +/- 3) x 10(9) kilograms.
13 ass of the rings is (1.54 +/- 0.49) x 10(19) kilograms (0.41 +/- 0.13 times that of the moon Mimas),
14 ogram (8 patients in cohort 2), 15.0 mug per kilogram (10 patients in cohort 3), or 30.0 mug per kilo
15 as 36% in the cohort that received 16 mg per kilogram (15 patients had a partial response or better,
16 umab at a dose of 130 mg (15.6%) or 6 mg per kilogram (15.5%) was significantly higher than that amon
17 ml per kilogram (1598 children) or 20 ml per kilogram (1598 children) and were followed for 180 days.
18 signed to receive a transfusion of 30 ml per kilogram (1598 children) or 20 ml per kilogram (1598 chi
19 store a specific energy of 41 watt-hours per kilogram (19.5 watt-hours per liter).
20 and 10% in the cohort that received 8 mg per kilogram (3 had a partial response).
21 to receive ipilimumab at a dose of 10 mg per kilogram (475 patients) or placebo (476) every 3 weeks f
22 22 patients who received a dose of 10 mg per kilogram, 5 (23%) had a complete response, 2 (9%) had a
23 weight (8 patients in cohort 1), 7.5 mug per kilogram (8 patients in cohort 2), 15.0 mug per kilogram
24 m (10 patients in cohort 3), or 30.0 mug per kilogram (9 patients in cohort 4).
25 ing >10(4) alloreplete iC9-T lymphocytes per kilogram achieved rapid reconstitution of immune respons
26 ram of daratumumab and 42 received 16 mg per kilogram, administered once weekly (8 doses), twice mont
27 ntravenous evinacumab at a dose of 15 mg per kilogram and 5 mg per kilogram and the placebo group wer
28 ere converted and reported in micrograms per kilogram and nanograms per puff, respectively, for easy
29 at a dose of 15 mg per kilogram and 5 mg per kilogram and the placebo group were -50.5 percentage poi
30 ose in cohort 1 was increased to 7.5 mug per kilogram and then to 15.0 mug per kilogram, and in cohor
31 ssed ecosystem, it had reached a mass of ~40 kilograms and was ~35 centimeters tall at the hip.
32 with vosoritide up to a dose of 15.0 mug per kilogram, and a sustained increase in the annualized gro
33 .5 mug per kilogram and then to 15.0 mug per kilogram, and in cohort 2, the dose was increased to 15.
34                 Ice blocks as small as a few kilograms are sufficient and have been obtained at two a
35 ing volumes in daily increments of 30 ml per kilogram as compared with 18 ml per kilogram.
36 hs, we measured the primary outcome, weight (kilograms), as well as frequency of self-weighing, objec
37 /regeneration power of 1,061/1,425 watts per kilogram at a 50 per cent state of charge and at minus 3
38 indicating that this individual weighed ~3.4 kilograms at hatching.
39 rtainty required for the redefinition of the kilogram based on the Planck constant.
40 more than 120 milligram artemisinic acid per kilogram biomass.
41 m pancreas tissue (IEQ/g) and digest IEQ per kilogram body weight (IEQ/kg), using multiple regression
42 utrient intake with lower total kilocalories/kilogram body weight in patients, compared to siblings a
43 t change in precipitation for every gram per kilogram change in the saturation specific humidity (its
44 nfidence level, using a low-background, 14.6-kilogram CsI[Na] scintillator exposed to the neutrino em
45 h a body mass index (calculated as weight in kilograms divided by height in meters squared) above 25
46                  Prepregnancy BMI (weight in kilograms divided by height in meters squared) categorie
47 ody mass index (BMI; calculated as weight in kilograms divided by height in meters squared) for age a
48 's change in body mass index (BMI; weight in kilograms divided by height in meters squared) is associ
49 ody mass index (BMI, calculated as weight in kilograms divided by height in meters squared) is associ
50 ean body mass index (calculated as weight in kilograms divided by height in meters squared) of 32.5.
51 SD) body mass index (calculated as weight in kilograms divided by height in meters squared) of 33.8 (
52 h a body mass index (calculated as weight in kilograms divided by height in meters squared) of 40 or
53 ive body mass index (calculated as weight in kilograms divided by height in meters squared) of 47.5 (
54 ody mass index (BMI, calculated as weight in kilograms divided by height in meters squared) of less t
55 ial body mass index (calculated as weight in kilograms divided by height in meters squared) over time
56 nus control) in BMI (calculated as weight in kilograms divided by height in meters squared) was -0.41
57 ody mass index (BMI; calculated as weight in kilograms divided by height in meters squared) was 25 to
58 index (calculated as calculated as weight in kilograms divided by height in meters squared) was 25.8,
59 ody mass index (BMI; calculated as weight in kilograms divided by height in meters squared) z score i
60 and body mass index (calculated as weight in kilograms divided by height in meters squared), age, sex
61 body mass index >25 (calculated as weight in kilograms divided by height in meters squared), and 49%
62 ody mass index (BMI; calculated as weight in kilograms divided by height in meters squared), and clin
63 es, body mass index (calculated as weight in kilograms divided by height in meters squared), and othe
64 ine body mass index (calculated as weight in kilograms divided by height in meters squared), and surg
65 and body mass index (calculated as weight in kilograms divided by height in meters squared), the odds
66 and body mass index (calculated as weight in kilograms divided by height in meters squared).
67 ody mass index (BMI, calculated as weight in kilograms divided by height in meters squared); fat and
68 sity (body mass index, measured as weight in kilograms divided by height in meters squared, of >/=30
69  Body mass index was calculated as weight in kilograms divided by height in meters squared.
70 her body mass index (calculated as weight in kilograms divided by height in meters squared; 30.6 vs 2
71 ody mass index [BMI; calculated as weight in kilograms divided by height in meters squared] >/=85th p
72 ts (body mass index [calculated as weight in kilograms divided by height in meters squared] of 35 or
73 ody mass index (BMI [calculated as weight in kilograms divided by height in meters squared]) and colo
74 dy mass index >/=35 [calculated as weight in kilograms divided by height in meters squared]) is assoc
75 ody mass index [BMI; calculated as weight in kilograms divided by height in meters squared], menopaus
76 mass index (BMI; calculated as the weight in kilograms divided by the height in meters squared) and c
77 ned as a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters)
78 es and a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters)
79  women with a body-mass index (the weight in kilograms divided by the square of the height in meters)
80 ho had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters)
81 having a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters)
82  and the mean body-mass index (the weight in kilograms divided by the square of the height in meters)
83 e in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters)
84 rweight or normal weight (BMI [the weight in kilograms divided by the square of the height in meters]
85 ble to the effects of taking off 7.4 and 5.7 kilograms during walking and running, respectively, and
86 alories per kilogram or grams of protein per kilogram early post-ALI diagnosis at recommended levels
87 dy weight every week (Cohort 1) or 25 mg per kilogram every 2 weeks (Cohort 2).
88 ery 2 weeks; nivolumab at a dose of 3 mg per kilogram every 2 weeks plus placebo; or ipilimumab at a
89 kilogram every 2 weeks); nivolumab (3 mg per kilogram every 2 weeks) plus ipilimumab-matched placebo;
90 am of body weight every 3 weeks or 10 mg per kilogram every 2 weeks) to either a training group (182
91  four doses, followed by nivolumab (3 mg per kilogram every 2 weeks); nivolumab (3 mg per kilogram ev
92  followed by nivolumab at a dose of 3 mg per kilogram every 2 weeks; nivolumab at a dose of 3 mg per
93 placebo; or ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses plus placebo, unti
94 mab-matched placebo; or ipilimumab (3 mg per kilogram every 3 weeks for four doses) plus nivolumab-ma
95 weight plus ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses, followed by nivol
96 ight every 4 weeks (39 patients) or 5 mg per kilogram every 4 weeks (36 patients) or placebo (34 pati
97 am of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for four doses, followed by nivo
98 eks or four doses of ipilimumab (at 3 mg per kilogram) every 3 weeks.
99 ar for early but not late protein (grams per kilogram) exposure (early-exposure HR: 8.9, 95% CI: 2.3,
100 being <3.1 x 10(-5) ampere-square meters per kilogram for meter-size homogeneous magnetized boulders.
101 ed and therefore prescribe the same dose per kilogram for oral and IV administration.
102  weight for the first infusion and 20 mg per kilogram for subsequent infusions) or placebo once every
103 s observed at doses of 15.0 and 30.0 mug per kilogram for up to 42 months.
104 o-income ratio, individual intake (grams per kilogram) for each of the other 2 protein sources, body
105 venous injections of 2.5 mmol gadolinium per kilogram (gadolinium-exposed group) or saline (control g
106 eived the starting dose of TY014 of 2 mg per kilogram had detectable YF17D-204 viremia; these partici
107 rticipants (who had received 4x10(13) vg per kilogram) had a median factor VIII expression of 13 IU p
108 rticipants (who had received 6x10(13) vg per kilogram) had a median factor VIII expression of 20 IU p
109 ght and one who had received 2x10(13) vg per kilogram) had factor VIII expression of less than 1 IU p
110 per kilogram than with a volume of 20 ml per kilogram (hazard ratio, 0.43; 95% CI, 0.27 to 0.69).
111  with 30 ml per kilogram than with 20 ml per kilogram (hazard ratio, 1.91; 95% CI, 1.04 to 3.49).
112  body weight (lower-dose group) or 65 IU per kilogram (higher-dose group).
113 ith 2 and 4 mg of intravenous tariquidar per kilogram; however, the lower dose was better tolerated.
114 corresponded to a dose of 4.5 U of FVIII per kilogram (ie, 9.0 U/dL).
115  evaluated ipilimumab at a dose of 10 mg per kilogram in patients who had undergone complete resectio
116  was correlated with the number of HSPCs per kilogram infused.
117 in vivo (10, 15, or 20 mg of doxorubicin per kilogram, intravenously, 48 h beforehand).
118 PAH quantitation successful at microgram per kilogram levels.
119 t laser beams and in the positions of the 40-kilogram mirrors of the Advanced LIGO detectors yield a
120  = 5) or with 5 or 7.5 mg of doxorubicin per kilogram (n = 5 each) and underwent dynamic small-animal
121 7% but carries the highest use intensity per kilogram of biomass (164.8 mg kg(-1)).
122  Ferumoxytol dose ranged from 1 to 11 mg per kilogram of body weight (<=510 mg iron; rate <=45 mg iro
123  once-daily subcutaneous dose of 2.5 mug per kilogram of body weight (8 patients in cohort 1), 7.5 mu
124 nfants to daily milk increments of 30 ml per kilogram of body weight (faster increment) or 18 ml per
125 combinant factor VIII at a dose of 25 IU per kilogram of body weight (lower-dose group) or 65 IU per
126 -range-based dose that approximated 6 mg per kilogram of body weight [322]) or placebo (319).
127 et dose of 2x10(6) anti-CD19 CAR T cells per kilogram of body weight after receiving a conditioning r
128 uzumab govitecan-hziy at a dose of 10 mg per kilogram of body weight after receiving at least two pre
129 ad received 6x10(12) vector genomes [vg] per kilogram of body weight and one who had received 2x10(13
130 were administered 2 MBq of (18)F-PSMA-11 per kilogram of body weight and then underwent low-dose PET/
131 y to receive nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks or docetaxel at a
132  to receive nivolumab, at a dose of 3 mg per kilogram of body weight every 2 weeks, or docetaxel, at
133  with ipilimumab at a dose of 3 or 10 mg per kilogram of body weight every 3 weeks for a total of 4 d
134 zumab (at a dose of either 2 mg or 10 mg per kilogram of body weight every 3 weeks or 10 mg per kilog
135 brolizumab (anti-PD-1) at a dose of 2 mg per kilogram of body weight every 3 weeks.
136 nistered pembrolizumab at a dose of 2 mg per kilogram of body weight every 4 to 6 weeks to eight adul
137 ntravenous evinacumab at a dose of 15 mg per kilogram of body weight every 4 weeks (39 patients) or 5
138 stered intravenously at a dose of 1000 U per kilogram of body weight every 48 hours for a total of si
139 ons of UB-421, at a dose of either 10 mg per kilogram of body weight every week (Cohort 1) or 25 mg p
140 usion of 20 ml of whole-blood equivalent per kilogram of body weight for anemia, regardless of hemogl
141 the IGF-IR inhibitor teprotumumab (10 mg per kilogram of body weight for the first infusion and 20 mg
142 ene at a dose of 5x10(11) vector genomes per kilogram of body weight in 10 men with hemophilia B who
143 umab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram of body weight in patients with advanced melano
144 tial dose of 7.5 or 9.4 mg of imetelstat per kilogram of body weight intravenously once a week until
145 or two doses of either tocilizumab (8 mg per kilogram of body weight intravenously) or placebo.
146 14 dose escalation to a maximum of 20 mg per kilogram of body weight occurred in 22 participants.
147 ls and Methods A total dose of 13.2 mmol per kilogram of body weight of each GBCA was administered in
148 following the administration of 0.2 mmol per kilogram of body weight of gadobenate dimeglumine, with
149         Patients (n = 5) received 0.5 mg per kilogram of body weight of indocyanine green (ICG) intra
150 ed 38% and 45% lower doses in milligrams per kilogram of body weight of paclitaxel and carboplatin, r
151 tagraxofusp at a dose of 7 mug or 12 mug per kilogram of body weight on days 1 to 5 of each 21-day cy
152 cutaneous dalteparin at a dose of 200 IU per kilogram of body weight once daily for 1 month followed
153 utaneous dalteparin (at a dose of 200 IU per kilogram of body weight once daily for the first month,
154 to receive intravenous plazomicin (15 mg per kilogram of body weight once daily) or meropenem (1 g ev
155 nistered intravenously at a dose of 3 mg per kilogram of body weight once every 2 weeks) or platinum-
156 closporine (starting at a dose of 3.5 mg per kilogram of body weight per day for 12 months).
157 ved hydroxyurea at a dose of 15 to 20 mg per kilogram of body weight per day for 6 months, followed b
158 mulsion providing DHA at a dose of 60 mg per kilogram of body weight per day or a control (soy) emuls
159 abidiol oral solution at a dose of 20 mg per kilogram of body weight per day or placebo, in addition
160 ntravenous infusion of serelaxin (30 mug per kilogram of body weight per day) or placebo, in addition
161 egimen (which included 10 mg of rifampin per kilogram of body weight per day) with an intensified reg
162 rea at a fixed dose (approximately 20 mg per kilogram of body weight per day) with dose escalation (a
163 -controlled trial of amitriptyline (1 mg per kilogram of body weight per day), topiramate (2 mg per k
164 19 patients), at a dose of 0.7 to 1.0 mg per kilogram of body weight per day, or itraconazole capsule
165 e baseline level or urine output <0.5 ml per kilogram of body weight per hour for >/=12 hours) and wa
166 me was the amount of glucose metabolized per kilogram of body weight per minute (Mbw) assessed during
167 enous levosimendan (at a dose of 0.2 mug per kilogram of body weight per minute for 1 hour, followed
168 n of either ularitide at a dose of 15 ng per kilogram of body weight per minute or matching placebo f
169 ving more than 0.2 mug of norepinephrine per kilogram of body weight per minute or the equivalent dos
170 vosimendan (at a dose of 0.05 to 0.2 mug per kilogram of body weight per minute) for 24 hours or plac
171     Peak oxygen consumption (milliliters per kilogram of body weight per minute) increased more in th
172 s infusion at a dose of 0.025 to 0.2 mug per kilogram of body weight per minute) or placebo, for up t
173 a to receive nivolumab at a dose of 1 mg per kilogram of body weight plus ipilimumab at a dose of 3 m
174 nergy deposition (constrained by the 2-W per kilogram of body weight SAR limitations) by using five s
175 periods: either 40 IU or 60 IU of CSL830 per kilogram of body weight twice weekly followed by placebo
176   A 100-kBq activity of (225)Ac-PSMA-617 per kilogram of body weight was administered bimonthly.
177 r in combination with daratumumab (16 mg per kilogram of body weight) (daratumumab group).
178 rial of nemolizumab (at a dose of 0.5 mg per kilogram of body weight) administered subcutaneously at
179 x10(5), 1x10(6), or 1x10(7) CAR-NK cells per kilogram of body weight) after lymphodepleting chemother
180 .5, 1.0, 2.5, 5.0, 10, and 20 x 10(8) MB per kilogram of body weight) and with control nontargeted MB
181 of gadodiamide (cumulative dose, 12 mmol per kilogram of body weight) by using inductively coupled pl
182  a 2:1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with either nivolumab
183 eceive pembrolizumab (at a dose of 10 mg per kilogram of body weight) every 2 weeks or every 3 weeks
184 fusion of evinacumab (at a dose of 15 mg per kilogram of body weight) every 4 weeks or placebo.
185 lar-weight heparin (100 IU of dalteparin per kilogram of body weight) or matching placebo administere
186 spatercept (at a dose of 1.00 to 1.25 mg per kilogram of body weight) or placebo for at least 48 week
187 mab (either 130 mg or approximately 6 mg per kilogram of body weight) or placebo in two induction tri
188 nous difelikefalin (at a dose of 0.5 mug per kilogram of body weight) or placebo three times per week
189 atercept (at a dose of 1.0 up to 1.75 mg per kilogram of body weight) or placebo, administered subcut
190 -7288 (1 mg, 4 mg, 8 mg, 12 mg, or 16 mg per kilogram of body weight) or placebo, in a 3:1 ratio.
191 siran (0.035, 0.10, 0.35, 1.0, or 2.5 mg per kilogram of body weight) or placebo.
192  single dose of either tocilizumab (8 mg per kilogram of body weight) or placebo.
193 ction of fitusiran (at a dose of 0.03 mg per kilogram of body weight) or placebo.
194 g regimens: nivolumab (at a dose of 1 mg per kilogram of body weight) plus ipilimumab (3 mg per kilog
195      Intravenous infusion of WST11 (4 mg per kilogram of body weight) was followed by using near-infr
196 ients received a low dose (6.7x10(13) vg per kilogram of body weight), and 12 received a high dose (2
197 of gadoterate meglumine (0.6 or 2.5 mmol per kilogram of body weight), gadodiamide (0.6 or 2.5 mmol/k
198 o receive low-dose crizanlizumab (2.5 mg per kilogram of body weight), high-dose crizanlizumab (5.0 m
199 ee intravenous infusions of ZMapp (50 mg per kilogram of body weight, administered every third day).
200 20 ml or 30 ml of whole-blood equivalent per kilogram of body weight, as determined in a second simul
201  strength (measured in watts and newtons per kilogram of body weight, respectively) were examined in
202  yields exceeding 5000 islet equivalents per kilogram of body weight.
203 KTE-X19 at a dose of 2x10(6) CAR T cells per kilogram of body weight.
204 h ferumoxytol at 3.0 T at a dose of 4 mg per kilogram of body weight.
205 ion of gadopentetate dimeglumine (0.1 mL per kilogram of body weight; Magnevist; Bayer Healthcare, Ea
206 ion of gadopentetate dimeglumine (0.1 mL per kilogram of body weight; Magnevist; Bayer Healthcare, Ea
207 ion of gadopentetate dimeglumine (0.1 mL per kilogram of body weight; Magnevist; Bayer Healthcare, Ea
208 ion of gadopentetate dimeglumine (0.1 mL per kilogram of body weight; Magnevist; Bayer Healthcare, Ea
209 ks; cumulative gadolinium dose, 7.2 mmol per kilogram of body weight; n = 6) or saline (n = 6) was ex
210 r square centimeter per hour (3660 moles per kilogram of catalyst per hour).
211 pansion phase, 30 patients received 8 mg per kilogram of daratumumab and 42 received 16 mg per kilogr
212 s (0 [control] and 0.25 and 1 milligrams per kilogram of dry soil) and two CeO2 NPs concentrations (0
213 trations (0 [control] and 500 milligrams per kilogram of dry soil) were investigated.
214 o 30 hertz, as well as up to 41.2 joules per kilogram of electrical energy per mechanical cycle, when
215 .33) in the diet group and by 7.02 mumol per kilogram of fat-free mass per minute (95% CI, 3.21 to 10
216  production from baseline, by 7.04 mumol per kilogram of fat-free mass per minute (95% confidence int
217 l, from 30.5+/-15.9 to 61.6+/-13.0 mumol per kilogram of fat-free mass per minute in the diet group a
218 nd from 29.4+/-12.6 to 54.5+/-10.4 mumol per kilogram of fat-free mass per minute in the surgery grou
219 4) and 5.37 (95% CI, 2.41 to 8.33) mumol per kilogram of fat-free mass per minute in the two groups,
220 te an externality cost of about US$1,500 per kilogram of fluoroquinolones administered in US broiler
221               Harmonized climate impacts per kilogram of food waste range from -0.20 kg of carbon dio
222  the number of aerosol particles emitted per kilogram of fuel burned and the microphysical properties
223 were injected with gadoteridol (0.1 mmol per kilogram of maternal weight).
224 apable of harvesting 2.8 liters of water per kilogram of MOF daily at relative humidity levels as low
225 etching coiled yarns generated 250 watts per kilogram of peak electrical power when cycled up to 30 h
226  over the first 48 hours, in milliliters per kilogram of predicted body weight (PBW).
227 ume assessments (evaluated in milliliter per kilogram of predicted body weight [PBW]) and daily asses
228 5-1.24; and tidal volume [in milliliters per kilogram of predicted body weight]: OR, 1.12, 95% CI, 1.
229 are most sensitive to the CO(2) released per kilogram of steel produced and the steel stocks per capi
230  4x10(13) vg per kilogram or 6x10(13) vg per kilogram of the gene therapy.
231 with an energy density of 460 watt-hours per kilogram of total composite electrode and about 100 per
232                             For example, per kilogram of weight loss, there was a 0.04-SD decrease in
233 standard deviation for the test, 36 mmol per kilogram of wet weight +/- 2 [range, 34-37 mmol/kg]; for
234 ted into the lactate platform to produce 196 kilograms of butyric acid per metric ton of beechwood.
235 e diet (985 000 000 tons of CO(2) eq or 3191 kilograms of CO(2) eq per capita per year), while a DGA-
236                                        Seven kilograms of corn flour were used to prepare the materia
237                       Each year, millions of kilograms of insecticides are applied to crops in the US
238 acturing practices) process that produced 24 kilograms of prexasertib monolactate monohydrate suitabl
239 .32% of total cannabis sales in Colorado (in kilograms of tetrahydrocannabinol) during that period.
240 llowed by dalteparin at a dose of 150 IU per kilogram once daily (dalteparin group).
241  for the first month, followed by 150 IU per kilogram once daily).
242 e immediate blood transfusion with 20 ml per kilogram or 30 ml per kilogram.
243 articipants who had received 4x10(13) vg per kilogram or 6x10(13) vg per kilogram of the gene therapy
244 at a dose of 0.225, 0.45, 0.9, or 1.8 mg per kilogram or a fixed dose of 80 mg).
245                   Providing kilocalories per kilogram or grams of protein per kilogram early post-ALI
246  (at a dose of 0.015, 0.045, or 0.075 mg per kilogram) or once monthly (at a dose of 0.225, 0.45, 0.9
247 f two doses of givosiran (0.35 or 1.0 mg per kilogram) or placebo (total of two injections 28 days ap
248  four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence
249 ht) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses,
250 of two doses of givosiran (2.5 or 5.0 mg per kilogram) or placebo once monthly (total of four injecti
251 weight), high-dose crizanlizumab (5.0 mg per kilogram), or placebo, administered intravenously 14 tim
252 -1.10 morphine equivalents in milligrams per kilogram per 48 hours; P = .004; I2 = 17%) and that acup
253 -0.01 morphine equivalents in milligrams per kilogram per 48 hours; P = .03; I2 = 86%) and in pain im
254 ears); the mean doses were 19.2+/-1.8 mg per kilogram per day and 29.5+/-3.6 mg per kilogram per day,
255 l DHA supplementation at a dose of 60 mg per kilogram per day did not result in a lower risk of physi
256 ment, the regimen of 3 mg of propranolol per kilogram per day for 6 months was selected for the final
257 cern was identified at doses up to 16 mg per kilogram per day in humans.
258 hat included higher-dose rifampin (15 mg per kilogram per day) and levofloxacin (20 mg per kilogram p
259 ilogram per day) and levofloxacin (20 mg per kilogram per day) for the first 8 weeks of treatment.
260 f body weight per day), topiramate (2 mg per kilogram per day), and placebo in children and adolescen
261 ith dose escalation (approximately 30 mg per kilogram per day).
262 g per kilogram per day and 29.5+/-3.6 mg per kilogram per day, respectively.
263  at a mean (+/-SD) dose of 17.5+/-1.8 mg per kilogram per day.
264 l, neopentylglycol, are about 389 joules per kilogram per kelvin near room temperature.
265        In sibling-controlled analyses, every kilogram per meter squared interpregnancy BMI change was
266 or 1 hour, followed by a dose of 0.1 mug per kilogram per minute for 23 hours) or placebo, with the i
267 mentary rocks in Gale crater is 1680 +/- 180 kilograms per cubic meter.
268  of Ceres with a core density of 2,460-2,900 kilograms per cubic metre (that is, composed of CI and C
269 e density of this outer shell is 1,680-1,950 kilograms per cubic metre, indicating a mixture of volat
270 of rocks overlying the megathrust of 150-200 kilograms per cubic metre.
271 age bulk density of the nucleus is 533 +/- 6 kilograms per cubic metre.
272 conducted to produce the target at roughly 3 kilograms per day using small continuous reactors, extra
273  nanofibers at rates that may exceed tens of kilograms per hour.
274 mass product (number-average molar mass 21.4 kilograms per mole) to a mixture of linear poly[7-26]cat
275 ly associated with body mass index (BMI) (in kilograms per square meter) and positively correlated wi
276 res and analyzed protein intake as grams per kilogram prepregnancy weight per day.
277 598, P < 0.001), peak oxygen consumption per kilogram (r = -0.474, P < 0.001), and 6-minute-walk dist
278 before vector administration vs. 49.3 IU per kilogram [range, 0 to 376] after administration; P=0.004
279 ), as was factor use (mean dose, 2908 IU per kilogram [range, 0 to 8090] before vector administration
280 from the milligram scale in batch to a multi-kilogram reaction in flow.
281 M:FFM had higher bias using kilocalories per kilogram recommendations; bias from several recommendati
282     Pretreatment with 1 mg of raclopride per kilogram reduced the apparent specific binding of (18)F-
283  melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates of recur
284 ntly the only CNCs available commercially in kilogram scale are obtained from wood pulp (W-CNCs).
285 ese conditions were executed on multigram to kilogram scale to provide three key enantiopure alpha-me
286  chemical processes for molecules on a multi-kilogram scale.
287 ows the preparation of ESF in 98% yield on a kilogram scale.
288  body weight (faster increment) or 18 ml per kilogram (slower increment) until reaching full feeding
289 s is possible by manufacturing a perfect one-kilogram sphere from a (28)Si-enriched single crystal.
290          At present, counting atoms in a one-kilogram sphere made of (28)Si-enriched silicon allows t
291 ith silicon used to manufacture previous one-kilogram spheres.
292 h fever, mortality was higher with 30 ml per kilogram than with 20 ml per kilogram (hazard ratio, 1.9
293 lower with a transfusion volume of 30 ml per kilogram than with a volume of 20 ml per kilogram (hazar
294        In the cohort that received 16 mg per kilogram, the median progression-free survival was 5.6 m
295 received tagraxofusp at a dose of 12 mug per kilogram, the primary outcome occurred in 21 (72%), and
296 rt 2, the dose was increased to 15.0 mug per kilogram; the patients in cohorts 3 and 4 continued to r
297  followed by a maintenance dose of 400 U per kilogram three times per week by subcutaneous injection
298 0(12) or 2 x 10(13) genome copies of AMT-060/kilogram was administered to 5 participants each.
299 ion with 20 ml of whole-blood equivalent per kilogram was triggered by new signs of clinical severity
300 e of either 130 mg or approximately 6 mg per kilogram were significantly higher than the rates among

 
Page Top